San Jose State University

SJSU ScholarWorks
Master's Theses

Master's Theses and Graduate Research

Fall 2012

Profiling flavonoid cytotoxicity in human breast cancer cell lines
Sina Yadegarynia
San Jose State University

Follow this and additional works at: https://scholarworks.sjsu.edu/etd_theses

Recommended Citation
Yadegarynia, Sina, "Profiling flavonoid cytotoxicity in human breast cancer cell lines" (2012). Master's
Theses. 4255.
DOI: https://doi.org/10.31979/etd.8h9d-vzta
https://scholarworks.sjsu.edu/etd_theses/4255

This Thesis is brought to you for free and open access by the Master's Theses and Graduate Research at SJSU
ScholarWorks. It has been accepted for inclusion in Master's Theses by an authorized administrator of SJSU
ScholarWorks. For more information, please contact scholarworks@sjsu.edu.

PROFILING FLAVONOID CYTOTOXICITY IN HUMAN
BREAST CANCER CELL LINES

A Thesis
Presented to
The Faculty of the Department of Biological Sciences
San José State University

In Partial Fulfillment
of the Requirement for the Degree
Master of Science

by
Sina Yadegarynia
December 2012

	
  

© 2012
Sina Yadegarynia
ALL RIGHTS RESERVED

	
  

The Designated Thesis Committee Approves the Thesis Titled

PROFILING FLAVONOID CYTOTOXICITY IN HUMAN
BREAST CANCER CELL LINES

by
Sina Yadegarynia

APPROVED FOR THE DEPARTMENT OF BIOLOGICAL SCIENCES
SAN JOSÉ STATE UNIVERSITY
December 2012

Dr. Brandon White

Department of Biological Sciences

Dr. Marc d’Alarcao

Department of Chemistry

Dr. Martina Bremer

Department of Mathematics

	
  

ABSTRACT
PROFILING FLAVONOID CYTOTOXICITY IN HUMAN
BREAST CANCER CELL LINES
by
Sina Yadegarynia
Flavonoids are part of a large family of polyphenols that are found
extensively in fruits and vegetables. This class of compounds has been of
considerable medical interest due to their anti-inflammatory and anti-cancer
activities. Although extensive effort has been made to identify the biological
effects responsible for the chemopreventive activity of these compounds, the
exact molecular mechanisms involved are not fully understood. In this study, we
focused on the cytotoxic effects of fourteen different flavonoids against a series
of breast cancer cell lines and evaluated the induction of cell cycle arrest at G1 or
G2/M phase as result of such treatment. We also assessed a possible structurefunction relationship for cellular cytotoxicity based on the various chemical
structures of flavonoids. The results showed that several flavonoids were
cytotoxic in all cell lines even in the absence of certain signaling pathways. In
addition, only some flavonoids were able to induce cell cycle arrest, suggesting
their cytotoxic potential may be independent of their ability to block cells at G1 or
G2/M phases. Our results enabled identification of certain structural properties
that are important for the anticancer activity of flavonoids. Finally, these results
suggested that cytotoxicity does not depend on a particular signaling pathway.
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INTRODUCTION
Cancer has been thought to be a preventable disease due to its slow
development and progression, taking many years to become invasive in a stepby-step manner [1]. Such property provides a great opportunity not only for early
detection, but also for prevention of the disease progression. Despite this, breast
cancer is the most frequently diagnosed cancer in women worldwide and ranks
second as a cause of cancer death [2]. It has been estimated that more than
two-thirds of human cancers could be prevented through lifestyle modifications,
such as dietary habits [3]. As early as 1676, when Dr. Wiseman proposed that
cancer might arise from “an error in diet,” diet has been considered an important
factor in cancer development [4].
Over the past several decades, there has been a particular interest in the
role of flavonoids in cancer prevention. Flavonoids are naturally occurring
polyphenols widely distributed in fruits, vegetables, and beverages including teas
and wine [4]. They represent a large portion of the compounds found in plants
with more than 5,000 varieties [5]. Flavonoids are reported to have a range of
biological activities including anti-oxidant, anti-inflammatory, and anti-tumorigenic
properties. In particular, flavonoids are active at different stages of cancer
development by protecting DNA from oxidative damage, activating carcinogen
metabolism and detoxification, preventing cellular proliferation, and/or inducing
cellular cytotoxicity [6-10].
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A survey of the literature shows a plethora of effects of flavonoids on tumor
and normal cell types, but the exact molecular mechanisms of flavonoid action
are not fully understood. Consequently, a careful characterization is needed to
establish a reference point for further analysis of flavonoids and potential
derivatives, which may provide a novel mechanism targeting clinical treatment
and prevention of cancer.

Table 1. Some of the signaling components of the cell lines in this study.
A (+) indicates present, (-) indicates absent, and (+/-) indicates weak expression.
IDC: Invasive Ductal Carcinoma; AC: Adenocarcinoma; ESR1: estrogen
receptor-1; PR: progesterone receptor; HER2: human epidermal growth factor
receptor-2.
Tumor
Type

Invasiveness

Gene
Cluster
Subtype

p53

ESR1

PR

HER2

BT-474

IDC

Strong

Luminal

Temperature
sensitive (E285K)

+

+

++

MCF-7

IDC

Weak

Luminal

Wild type

+

+

+

MDA-MB-231

AC

Strong

Basal

Nonfunctional
(R280K)

-

-

-

SK-BR-3

AC

Strong

Luminal

Missense (R175H)

-

-

++

ZR-75-1

IDC

Moderate

Luminal

Wild type

+/-

+

+/-

Cell Line

We, therefore, conducted a study to characterize the effects of fourteen
flavonoids on a variety of human breast cancer cell lines (Table 1 and 2). It has
been determined that these commercially available breast cancer cell lines mirror
the genomic, transcriptional, and biological heterogeneity of the primary tumors
[11]. These cell lines were selected based upon the presence of mutations
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Table 2. Sub-classes and chemical structures of flavonoids in this study.
OMe indicates methylated analogues, methylapigenin: 5,7,4’-trimethoxyflavone.	
  
Subclasses and Structures

Name

Flavones

Apigenin
Methylapigenin

Substitution
5

6

7

8

2’

3’

4’

5’

OH
OMe

H
H

OH
OMe

H
H

H
H

H
H

OH
OMe

H
H

OH

H

OH

H

H

H

H

H

OH
OMe

H
H

OH
OMe

H
H

H
H

OH
OMe

OH
OMe

H
H

OH

H

OH

H

H

H

OH

H

Myricetin
Quercetin
Methylquercetin

OH
OH
OMe

H
H
H

OH
OH
OMe

H
H
H

H
H
H

OH
OH
OMe

OH
OH
OMe

OH
H
H

Flavanones

Naringenin
Methylnaringenin

OH
OMe

H
H

OH
OMe

H
H

H
H

H
H

OH
OMe

H
H

Flavanol

(+)-Catechin

OH

H

OH

H

H

OH

OH

H

Isoflavones

Daidzein
Genistein

H
OH

H
H

OH
OH

H
H

H
H

H
H

OH
OH

H
H

Chrysin
Luteolin
Methylluteolin

Flavonols

Kaempherol

Modified from Yadegarynia et al. [12]
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in various signaling pathways. Mutations are reported in estrogen receptor-1
(ESR1), human epidermal growth factor-2 (HER2/ERBB2), progesterone
receptor, and tumor suppressor protein (p53). These cell lines have been used
in many studies to individually investigate the role of each flavonoid (Table 3).
For comparison with a non-transformed cell type, we used normal human
mammary epithelial cells (HMEC) with a lifespan of only 15 to 20 passages in
culture. HMECs are not immortalized, unlike MCF10A which have been
previously used in studies [13]. Such information may be used to help elucidate
the specific signaling pathways utilized by flavonoids for the induction of cellular
cytotoxicity.

Table 3. A survey of literature for effects of the flavonoids on breast cancer
cell line proliferation and cytotoxicity.
Cell Line

Flavonoid Used

Reference

BT-474

Apigenin, Genistein

[14, 15]

MCF-7
MDA-MB-231

Apigenin, Catechin, Genistein, Kaempherol,
Myricetin, Naringenin, Quercetin
Apigenin, Genistein, Kaempherol, Naringenin,
Quercetin

[16-24]
[6, 17, 25-37]

SK-BR-3

Apigenin, Genistein, Quercetin

[38-40]

ZR-75-1

Apigenin, Genistein, Kaempherol, Quercetin

[41-45]

MCF10A/HMEC

Apigenin, Daidzein, Genistein, Quercetin,
Naringenin

[13, 24, 46-49]

In this study, we showed that some flavonoids induced cell death in all cell
lines tested, including HMECs. Furthermore, we suggest that flavonoids might
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induce cellular cytotoxicity through a generalized, signaling pathwayindependent, mechanism.
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LITERATURE REVIEW
Chemistry of Flavonoids
Plants are rich sources of chemically diverse compounds, many with
beneficial properties to human health. Consequently, about 50% of the
anticancer therapeutic agents known are derived from plants [50]. For example,
compounds such as Taxol and vinca alkaloids act to destabilize the microtubules
of cancer cells, preventing the rapid proliferation of tumors [51]. Polyphenolic
compounds make up one of the most abundant groups of compounds in the plant
kingdom [9]. They are secondary metabolites involved in many important
functions in plants. Some of these functions include UV protection, defense
against biotic and abiotic stresses, pigmentation, and normal growth and
development [52]. Polyphonels are divided into 10 general classes with more
than 8,000 compounds identified to date. The most abundant occurring
polyphenols are flavonoids, accounting for about 60% of the polyphenols.
Flavonoids are divided into six sub-classes based on their chemical structure,
including flavanols, flavones, flavanones, flavonols, isoflavones, and
anthocyanidins.
The chemical structure of flavonoids is characterized by a
diphenylpropane carbon skeleton of C6-C3-C6, where two benzene rings are
linked by a 3-carbon chain forming a heterocyclic pyran or pyrone ring with an
oxygen. Differences in the number and arrangement of the hydroxyl groups lead

6

to variations within each group. Flavonoids may be hydroxylated at positions 3,
5, 7, 3’, 4’, and/or 5’ (Table 2). Except for isoflavones, where the B-ring is
attached at the 3-position on the pyran, the rest of the sub-classes have the Bring attached at the 2-position. The flavones contain a 2,3-unsaturation in the Cring, and the flavonols possess both the 2,3-unsaturation and a hydroxyl group at
the 3-position. The flavanones have a saturated 2,3-bond, and the flavanols also
possess a hydroxyl group at the saturated 3-positions. The names and
structures of the flavonoids in the study are listed in Table 2.
The anti-oxidant activity of these compounds is due to the presence of
these phenolic hydroxyl groups, which create their electron-donating property
against free radicals [53]. At the same time, flavonoids are frequently found
attached to sugars almost exclusively as β-glycosides, where a hydroxyl group at
positions 3 or 7 is substituted by various glycosides [54, 55]. Glucose is the most
common residue attached, which ultimately increases the water solubility of
flavonoids in plants [52, 56]. The deglycosylation of flavonoids may be an
important first step for their absorption in the body, and this rate is dependant on
both the structure of the polyphenol and the position or the nature of the attached
sugars [55].
Consequently, due to such diversity, flavonoids are able to interact with
many targets and influence various signaling pathways. This further emphasizes
the importance of studying their molecular chemistry.
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Flavonoids in Food
In the 1930s, scientists Rusznyák and Szent-Györgyi showed that a
substance from lemon peel reduced capillary permeability and was effective for
purpura treatment [57]. They named it “Vitamin P,” P for permeability, and later
reported that it consisted of a mixture of polyphenols. Flavonoids lost their status
as vitamins in the 1950s, when it was shown that their removal from the diet did
not cause any abnormalities. However, studies since the 1980s have been
providing strong implications regarding their protective effects against many
chronic diseases, such as coronary heart disease and cancer. As the result, the
World Health Organization (WHO) recommended an intake of about 400 g/day of
fruits and vegetables, which may save up to 2.7 million lives annually [58].
Flavonoids are still considered to be a non-essential dietary components
found ubiquitously in foods and beverages of plant origin, such as vegetables,
fruits, teas, wine, and chocolate (Table 4). Sub-classes of flavonoids, however,
do not seem to be uniformly distributed in many foods. For example, grapefruit
juice has been shown to contain around 200-850 mg/L of total flavonoids, among
which naringenin is about 145-638 mg/L and the most abundant flavonoid [59].
Orange juice, however, mainly contains the flavanone hesperidin at about 200450 mg/L [60]. Green tea and red wine are rich sources of flavanol catechins, as
high as 1,000 mg/L, while soy foods are rich source of isoflavones, such as
genistein and daidzein [61].
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Table 4. Sub-classes and common dietary sources of flavonoids.
Flavonoid sub-class

Major Food Sources

Flavonols

Onions, spinach, cherries, apples, broccoli, kale, tomato, berries, almond,
tea, red wine

Flavones

Parsley, thyme, celery, peppers, rosemary

Isoflavones

Soybeans, legumes, peanuts, fava beans, red clover

Flavanols

Apples, tea, red wine, chocolate

Flavanones

Oranges, grapes, lemons, psoralea

Anthocyanidins

Berries, grapes, cherries, plums, cashews, hazelnuts, eggplant

It has been estimated that the total amount of flavonoid consumed in the
western diet is about 1 g/day [62], but some studies indicate that this amount can
vary widely [63]. This may be due to the great diversity of flavonoids and the
limited data on their content in foods. Another complication is the fact that the
flavonoid content is influenced by many other factors, including season, climate,
sunlight, and food preparation [64]. However, in 2011 the U.S. Department of
Agriculture (USDA) compiled and published an updated database on the 26 most
commonly occurring flavonoids in over 500 foods [65].
Flavonoids as Chemopreventative Agents
Even though cancer is attributed to genetic mutations, such as the BRCA1
and BRCA2 genes in breast cancer, known genetic defects only account for up to
10% of all cases. On the other hand, lifestyle factors, including diet, smoking,
and physical activity, account for the majority of cancer cases [66, 67]. A lot of
the epidemiological data from case-control and cohort studies have found an
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inverse relationship between the risk of developing certain cancers and the
consumption of vegetables and fruit [62, 68-70]. The American Institute for
Cancer Research published a comprehensive report in 2008, which concluded
that there was convincing evidence for a statistically significant decrease in
development of certain cancers with consumption of fruits and vegetables [71].
Additionally, lung, colon, prostate, and breast cancer have been shown to
be more common in Western rather than in Eastern countries [7]. More
specifically, it has been reported that China and Japan, where the daily
consumption of soy products reaches up to 100 mg as opposed to a few
milligrams in Western countries, have one third the incidence of prostate and
breast cancer [72].
Much compelling data highlights the important role of flavonoids as
chemopreventative agents. Through extensive studies, flavonoids have been
shown to possess many biochemical and pharmacological actions that may
significantly affect cellular systems. Numerous studies report on the antiflammatory, anti-oxidant, antiallergic, hepatoprotective, antithrombotic, antiviral,
and anticarcinogenic activities of these compounds [73] (Table 5).
Chemoprevention has been defined as the prevention, inhibition, or
reversal of carcinogenesis during the progression of cancer, before cellular
invasion across the basement membrane by pharmacological agents like
flavonoids [74]. As a result of this slow development and progression, cancer
has been thought to be a preventable disease.
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Table 5. Proposed mechanisms for chemoprevention by phytochemicals.
Antioxidant activity to reduce the role of ROS and other free radicals
Inhibition of cell proliferation, oncogene expression, signal transduction pathways,
inflammation, cell adhesion and invasion, nitrosation and nitration
Enzyme inhibition:
-Phase I enzyme (blocking activation of carcinogens)
-Cyclooxygenase-2
-Inducible nitric oxide synthase
-Xanthine oxidase
Induction of cell differentiation, cell-cycle arrest, apoptosis, tumor suppressor
gene expression
Induction of enzymes and enhancement of detoxification
-Phase II enzymes
-Glutathione peroxidase
-Catalase
-Superoxide dismutase
Enhancement of immune response
Antiangiogenesis
Prevention of DNA adduct formation or DNA intercalation
Regulation of estrogen and steroid hormone metabolism
Modified from Liu et al. [75]

Furthermore, carcinogenesis is a very complex multistep process that
includes tumor initiation, promotion, and progression from the initial exposure to
carcinogen and the ultimate development of cancer [76] (Figure 1). As
chemopreventive agents, flavonoids are active at different stages of cancer
development interfering with the overall process through various mechanisms
such as modulating mitogenic signaling, survival/apoptotic signaling, cell-cycle
regulation, angiogenesis, and metastatic effects in the cells [77]. Studies show
that targets in various signal transduction pathways vary depending on the origin
of cancer. For example, flavonoids may inhibit the activity of DNA topoisomerase
I/II [78], release of cytochrome c from mitochondria and subsequent activation of
caspases-3, 8 and 9 [79, 80], down-regulation of Bcl-2 and Bcl-xl expression
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ii.	
  Promotion	
  

• ROS Scavenging
• Alter carcinogen
metabolism

Normal Cell

i.	
  Initiation	
  

Initiated
Cell

• Induce apoptosis
• Induce cell cycle
arrest
• Inhibit angiogenesis

• Induce detoxification
• Prevent DNA damage
• Induce apoptosis

Benign
Tumor

Malignant
Tumor
• Induce apoptosis
• Inhibit angiogenesis
• Inhibit invasion

iii.	
  Progression	
  

Figure 1. Model of carcinogenesis and potential consequences of
flavonoids on cancer progression. Carcinogenesis is a complex multistep
process that can be activated by various agents including ROS. Steps: i.
Initiation: the exposure or uptake of the carcinogen by a cell and its interaction
with the DNA. ii. Promotion: the persistence and replication of the abnormal
cells, originating preneoplastic cells. iii. Progression: uncontrollable growth of
tumors with gradual conversion of premalignant cells to neoplasia with potential
for metastasis and angiogenesis [9]. Carcinogens are known to affect many
signaling pathways, such as: modulation of transcription factors (e.g. NF-κB, AP1, STAT3), apoptotic proteins (e.g. Akt, Bcl-2, Bcl-XL, caspases, PARP), protein
kinases (e.g. EGFR, HER2, MAPK), cell cycle protein (e.g. cyclins, cyclindependant kinases), cell adhesion molecules, COX-2, and growth factor
signaling pathways [7]. Flavonoids may interact with many cellular molecules
and interfere with the growth and progression of the tumor. For example,
kaempherol can stop initiation by inhibiting the metabolic activation of the
carcinogens by phase I enzymes (CYPs) or their interaction with DNA.
Naringenin and quercetin, on the other hand, can stimulate detoxification of
carcinogens by activating phase II enzymes. Genistein can interfere with
promotion and progression by inducing cell cycle arrest, apoptosis and/or
inhibiting metastasis and angiogenesis [81].
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and/or up-regulation of Bax and Bak expression leading to apoptosis [80]. While
specific molecules have been identified to be involved in the process, the
induction and regulation still remains unexplained.
One of the well studied roles of flavonoids is their anti-oxidant potential
against Reactive Oxygen Species (ROS), which cause DNA damage and
promote carcinogenesis in biological systems [82]. Since an imbalance between
production of ROS and the body’s anti-oxidant defenses can cause many chronic
diseases, the anti-oxidant activity of flavonoids has been regarded as the main
biological activity for many years. However, recent bioavailability data has
challenged this notion. It has been shown that the concentrations of flavonoids
are limited due to their low absorption by the body and short half-life in plasma.
In addition, extensive metabolism by the body significantly alters their redox
potential. As a result, their concentrations in the tissue are lower than
endogenous anti-oxidants, limiting such efficacy in vivo [52, 70].
Many other studies have, therefore, linked the anti-cancer function of
flavonoids to modulation of various molecular targets involved in many
intracellular signaling pathways such as cell signaling, mitogenic signaling, cell
proliferation, cell cycle regulation, angiogenesis, and metastatic events (Table 6).
For example, flavonols and flavonones interfere with the activation of
carcinogens by inhibiting cytochrome P450 enzyme of CYP1A family [69]. Some
flavonoids also interfere with the activities of many other enzymes such as βglucuronidase, lipoxygenase, cyclooxygenase (COX), nitric oxide synthase
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(NOSs), monooxygenase, thyroid peroxidase (TPO), xanthine oxidase (XOs),
mitochondrial succinoxidase and NADH-oxidase, phosphodiesterase (PDE),
phospholipase A2 (PLA2), and protein kinase [83, 84].

Table 6. Some of the molecular targets of flavonoids.
Anti-Apoptotic
Proteins
↓Bcl-2
↓Bcl-XL
↓Survivin
↓TRAF1
↓cFLIP

Apoptotic
Proteins
↑Caspases
3, 7, 8, 9
↑PARP
↑Bax

Cell-Cycle
Proteins
↓Cyclin D1, E
↑p21/WAF
↑p27Kip/Cip
↓CDK1,2,4,6,7

Growth Factor
Pathways
↓TNF
↓EGF
↓IFN-γ
↓IL-1,2,6,8
↓Erythropoietin

Transcription
Factors
↓NF-κB
↓AP-1
↓STAT1,3,5
↓β-catenin
↑p53

Protein
Kinases
↓IKK
↓EGFR
↓HER2
↓Akt
↓MAPK

Modified from Aggarwal et al. [7]

Molecular Targets of Flavonoids
Flavonoids have been shown to possess many biochemical and
pharmacological actions that may significantly affect cellular systems by
modulating various proteins in signaling cascades (Table 6). While specific
molecules have been identified to be involved in these processes, the induction
and regulation of many remain unexplained. Some of the molecular targets are
highlighted here.
Nuclear Factor-κB (NF-κB) is a family of proteins that are pro-inflammatory
transcription factors that can promote carcinogenesis [85]. Upon activation by
ROS, cytokines, and other carcinogens, NF-κB is translocated into the nucleus
and is able to regulate expression of more than 200 genes, which may suppress
apoptosis and promote proliferation, invasion, metastasis, and inflammation [86].
Studies have suggested that apigenin, catechin, genistein, quercetin,
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kaempherol, and luteolin are potent inhibitors of the NF-κB signaling cascade
through various mechanisms such as inhibition of Bcl-2, Bcl-XL, cyclin D1, matrix
metalloproteases (MMP), and vascular endothelial growth factor (VEGF) [7, 87,
88]. Activation of the serine/threonine protein kinase (Akt) has also been shown
to support cancer cell survival through activation of NF-κB and inhibition of
apoptosis [89]. Genistein has been shown to inhibit Akt activation through
epidermal growth factor (EGF) inhibition [7].
Activator Protein-1 (AP-1) is also a transcriptional activator that regulates
expression of several genes involved with apoptosis, cell proliferation, cell
transformation, inflammation, and innate immune response [90]. For example,
AP-1 may activate cyclin D1 and repress tumor-suppressor genes such as p53.
Catechin and quercetin have been reported to suppress the activation of AP-1
[91, 92].
In addition, defect in the regulation of cell cycle also leads to cancer. For
example, overexpression of major cell cycle regulators, such as cyclins and
cyclin-dependant kinases (Cdk), leads to promotion of carcinogenesis [93].
Prostate, lung, and breast cancer have been shown to overexpress cyclin D1,
which is regulated by NF-κB [94-96]. As a result, NF-κB inhibitors such as
genistein and apigenin are able to induce cell cycle arrest at gap-2 (G2) phase
and halt the proliferation of cancer cells [7, 97].
Apoptosis is also an essential part of homeostasis that involves a series of
events inducing programmed cell death. Defects in the regulation of apoptosis
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have also been linked to several factors including NF-κB and AP-1. Flavonoids
have been shown to induce apoptosis in some cancer cell lines, while their
molecular mechanism is not fully understood. For example, genistein causes
apoptosis in MDA-MB-468 cells, but not in MCF-7, ZR-75, or MDA-231 cells [98].
Suggested mechanisms include inhibition of NF-κB and AP-1, DNA
topoisomerase I/II activity, regulation of heat shock proteins, and release of
cyctochrome c with activation of caspases-9 and 4 [8, 99]. Catechin, on the
other hand, causes apoptosis by down regulating the expression of apoptosis
suppressor proteins, such as Bcl-2 and Bcl-XL [100].
Tumor-suppressor p53 is a transcription factor also involved in many cell
processes including DNA repair, cell cycle control, and apoptosis. Upon
activation, p53 expresses genes that induce apoptosis, cause cell cycle arrest, or
inhibit angiogenesis [86]. Many flavonoids, therefore, have been shown to
activate p53 or its target genes. For example, luteolin induces cell cycle arrest
and apoptosis by activating p53, p21, and Bax genes [86].
Finally, many cancers, including liver, breast, lung, and skin, contain
overexpression of the enzyme cyclooxygenase-2 (COX-2), which leads to
inflammation [101]. Several transcription factors, such as NF-κB and AP-1,
cause this overexpression. Therefore, flavonoids such as luteolin, genistein,
apigenin, and catechin inhibit these transcriptional factors and suppress COX-2
transcription.
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Bioavailability of Flavonoids
Bioavailability refers to the amount of any substance that reaches the
plasma unchanged. Thus bioavailability of flavonoids determines their activity in
vivo. Most of polyphenols are present in the form of esters, glycosides, or
polymers (called tannins [63]) produced by the plants or as a result of food
processing, which also increases their water solubility [52, 60]. Therefore, there
is little chance of absorption by passive diffusion, ATP pumps, or transporters
when orally administered [52]. In order to be absorbed by the body, they must be
hydrolyzed or deglycosylated by the intestinal enzymes or the colonic microflora
[102]. Even though the exact modifications of flavonoids during metabolism are
not yet fully understood, polyphenols are further broken down and modified by
methylation, sulphation, and glucuronidation in the liver and/or kidney [103]. This
is also a common metabolic detoxification process that facilitates biliary and
urinary elimination of xenobiotics by increasing their hydrophilicity. It has also
been reported that for many of the polyphenols the plasma baseline levels are
reached within 24 hours of consumption [104].
Flavonoids undergo extensive phase I deglycosylation and phase II
metabolism by biotransformation enzymes in the small intestine epithelial cells
and liver [83, 105]. Three general processes are involved: conjugation with
thiols, oxidative metabolism, and P450-related metabolism [83]. Extensive
conjugation of the free hydroxyl groups is thought to be the main reason for low
oral bioavailability of flavonoids in vivo [106]. As the result, polyphenols are
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present in low concentrations after consumption and are eliminated shortly
afterwards. These metabolic modifications of flavonoids alter the structure and
ultimately the redox potential of these compounds. Further studies are needed to
better understand their bioavailability in vivo.
Moreover, intestinal absorption of polyphenols has been shown to vary
greatly. For example, in vivo studies have reported a 0-60% absorption of the
original dose with a half-life of 2-28 hours in the body [107]. Many factors such
as the sugar moiety or gut microflora affect account for these variations. In
addition, the amount of flavonoids absorbed in the intestine varies depending on
the sub-classes. For example, only 0.2-0.9% of tea catechins are absorbed as
opposed to 20% for quercetin and isoflavones [69]. Isoflavones appear to have
the highest bioavailability, while flavonols appear to have the lowest
bioavailability but the highest half-life in plasma. Flavanols appear to have the
shortest half-life [107, 108]. In addition, bioavailability of flavonoids also varies
based on the source of food consumed. For example, quercetin absorption from
onion is four times that of apple or tea [69].
It is important to note that the most common flavonoids in the diet may not
be the most active in vivo, and that the metabolites in the plasma may also not
be the original compound. As a result, many inconsistencies on the
bioavailability of flavonoids have been reported. Compiling comprehensive and
reliable data in vivo is thus essential, yet has proven to be challenging.
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Higher Bioavailability and Metabolic Stability of Methylated Flavonoids
Methylated flavonoids have been studied less extensively due to the
absence of hydroxyl groups, and because ultimately they lack anti-oxidant
properties. However, recent studies have shown that methylated flavonoids were
metabolically stable and experienced slower hepatic metabolism compare to the
unmethylated compounds [109]. Studies in rats have shown that methylchrysin
had a higher oral bioavailability and tissue accumulation, particularly in the liver,
compared to the unmethylated compound [110]. Methylated compounds have
also been shown to have a higher rate of intestinal permeability [106].
Although most of the compounds studied are synthetic, some methylated
flavonoids have been identified in plants. For example, methylapigenin is
present in citrus fruits and methylchrysin is present in fruits and leaves of
neotropical nutmeg species [110]. Since more in vivo studies relate the
chemoprevention of flavonoids to the modulation of cellular signaling pathways,
as opposed to their anti-oxidant effect, greater attention should be given toward
methylated polyphenols.
It is important to mention that a different mechanism of action has been
suggested for the methylated analogues of flavonoids, when comparing their cell
cycle arrest data. For example, apigenin have been shown to induce arrest in
the G2/M phase, while methylapigenin and methylchrysin arrest most cells in the
G1 phase [110]. Methylated flavones have also been shown to have a higher
potency, which could be attributed to their higher accumulation in the cell [111].
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Consequently, methylation of flavonoids not only increases their oral
bioavailability, but also their metabolic stability and tissue accumulation. In
addition, methylation of the hydroxyl groups has shown to not interfere with the
anti-proliferative capacity of flavonoids [112]. Taken together, methylated
flavonoids may prove to be more effective in vivo. However, more extensive
studies on their mechanisms of action are still required.
Structure-Function Relationship of Flavonoids
It has been suggested that the structure of flavonoids dictates their
bioactivity. In addition, that specific structural features are involved in whether or
not flavonoids can act as a potent inhibitors of molecular targets such as protein
kinase C (PKC), tyrosine kinase, and PI 3-kinase [113]. There is still no clear
consensus on structure-function relationships based on the various structures of
sub-classes. While some studies have found no obvious relationship [72, 114],
others have highlighted important structural features. For example, the presence
of 2,3-unsaturation on the C-ring and the number and substitution of hydroxyl
groups on the A and B-rings have shown to greatly affect the anti-oxidant and
anti-cancer activity of these compounds [83, 115].
One of the important structural features of flavonoids is the presence of
2,3-unsaturation in the C-ring (Figure 2). The presence of this double bond has
shown to enhance the anti-proliferative effect of the flavonoids [83, 112, 115]. In
addition to the presence of this double bond, number and substitution of hydroxyl
groups appear to affect the anti-oxidant potential of flavonoids. For example,
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three adjacent hydroxyl groups on the A or B-ring (e.g., myricetin with 3’, 4’, 5’OH groups) results in a strong anti-proliferative effect [112]. Therefore, it has
been suggested that more hydroxyl groups lead to better ROS scavenging and
anti-inflammatory activity [116]. In terms of positions, the hydroxyl group at 4’ in
the B-ring improves the anti-proliferative effect of the flavonoids, evident when
comparing apigenin (with 4’-OH group) and chrysin (without 4’-OH) [117].
Flavonoids with 5- and 7-OH groups in the A-ring (e.g., apigenin, luteolin,
quercetin, and kaempherol) significantly inhibit lipogenesis [118]. Kaempherol,
myricetin, and quercetin (with 3, 5, and 7-OH groups) have been shown to have
higher anti-oxidant activity [119].

Figure 2. General structure of flavones.

Therefore, many researchers have concluded that the presence of a
particular molecular structure leads to inhibition of several kinases, which
ultimately induces cell cycle arrest and apoptosis. It has been suggested that the
presence of the 4-oxo group, the 2,3-double bond in the C-ring, and the 3’ and 4’-
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OH in the B-ring (so-called catechol group) enhances the anti-oxidant and antiproliferation activity of flavonoids [53, 73, 112, 116-118, 120].
Biphasic Effects of Flavonoids
Several flavonoids have been shown to have a biphasic effect on
apoptosis. For example, apigenin and chrysin were shown to stimulate
proliferation at low concentrations, while their methylated analogs did not [110].
The authors concluded that at lower concentrations, apigenin activates ERαmediated gene transcription and caused growth stimulation. At higher
concentrations, on the other hand, apigenin down regulates protein levels of ERα
and inhibits protein kinases p38, MAPK, PKA, and Akt, leading to growth
inhibition [16]. Similarly, genistein has been shown to stimulate growth of ERpositive cancer cells, such as MCF7, at lower concentrations by acting as an
estrogen agonist [39]. At higher concentrations, however, genistein inhibits cell
growth by being an estrogen antagonist and inhibiting tyrosine kinase activity
[121, 122]. These results highlight the importance of more extensive studies into
the biphasic effect of some flavonoids, especially in ER-positive cancer cells.
Flavonoids Used in the Study
Flavonoids have been shown to modulate many molecular targets
affecting various cellular pathways within cells. Some of the specific molecular
targets of flavonoids used in our study and their effects on various pathways are
listed in Table 7.
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Table 7. Molecular targets of flavonoids used in this study.
Flavonoid
Apigenin
Catechin
Chrysin
Daidzein

Molecular targets
↓ NF-κB, ↑ IκBα
↑ RyR1, ↓ NF-κB
↓CDK6/cycD, ↓TBK1
↓ NF-κB, ↓ STAT-1, ↓ iNOS

Genistein
Kaempherol
Luteolin
Myricetin
Naringenin
Quercetin

↓ NF-κB, ↓ NF-κB-DNA binding, ↑ IκBα, ↓ IL-8
↓ PGE2, ↓ COX-2, ↓ NF-κB
↓ NF-κB, ↓TBK1
↓ COX-2, ↓ NF-κB
↓ iNOS, ↓ NO, ↓ NF-κB, ↓ STAT-1
↓ NF-κB, ↓ AP-1

Data gathered from [123-127]

Apigenin, chrysin, and luteolin are flavones found in limited quantities in
leafy vegetables and other herbs. Apigenin and luteolin have been reported to
induce cell cycle arrest at G2/M phase. They also induce apoptosis through
various pathways including activation of caspases-3, 6, and 9, suppression of Akt
and NF-κB, and induction of tumor suppressor p53 [41, 128-130]. Chrysin has
been reported to increase the expression of PPARs, causing cytoplasmic lipid
accumulation [131].
Flavonols are the most abundant flavonoid found in leafy vegetables,
apples, onions, broccoli, and berries. Kaempherol, myricetin, and quercetin fall
into this sub-class of flavonoids. Kaempherol has been shown to induce
apoptosis through mitochondria-dependent pathways and induce cell cycle arrest
through down-regulation of serine/threonine protein kinase (PLK-1) [132].
Kaempherol has also been reported to have a minimal apoptotic effect in MDAMB-231 cells, as opposed to MCF-7 cancer cell line [33]. Myricetin has been
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shown to suppress topoisomerase II [133]. Quercetin is the most ubiquitous
dietary flavonoid with a daily intake of 25-30 mg in Western countries [66].
Quercetin has been shown to induce cell cycle arrest at the G1 or G2/M phase,
depending on the cell lines [40], and cause anti-proliferation by increasing tumor
suppressor p53, activation of caspases-6, 8, and 9, and suppression of NF-κB,
COX-2, and Akt [66, 99, 134].
Naringenin is a flavanone found predominately in citrus fruits and their
juices. Naringenin has been shown to impair glucose uptake and inhibit cellular
proliferation in vitro [129, 135]. It has also been noted that naringenin causes
apoptosis through a p53-independent induction of caspase-3, activation of
p38/MAPK, and inactivation of phosphatidylinositol 3-kinase (PI3K) and Akt [123,
135-137].
Catechin is a flavanol found extensively in tea, apple, grapes, chocolate,
and red wine. Many studies have highlighted the chemopreventative potential of
catechins derived from various green and black teas against several cancers
including cervical, prostate, and hepatic malignancies [66].
Genistein and daidzein are naturally abundant isoflavones found in soy
products, tea, fruits, and vegetables. They are commonly known as
phytoestrogens, with estrogenic activity in the cell [21]. Since approximately 70%
of all breast cancers express ER [39], ER status is an important factor in
chemopreventative potential of phytoestrogens and requires careful
consideration. It has been reported that some breast cancers are dependent on
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estrogen for sustained growth, and such phytoestrogens bind to the ER and
activate it [138]. It has been shown that both isoflavones modulate multiple
signaling pathways and are able to induce apoptosis via a caspase-3 mediated
pathway [139]. Daidzein has been shown to disrupt mitochondrial membrane
potential leading to cytochrome c release and to induce cell cycle arrest at the
G1 and G2/M phases by up regulating expression of p27 [18, 140]. Therefore,
daidzein disrupts tumorogenesis through a cell cycle mediated pathway.
Genistein has been shown to down regulate Bcl-2, up regulate Bax, and inhibit
proliferation by inducing apoptosis through the MAPK pathway [121, 141].
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MATERIALS AND METHODS
Materials
Flavonoids and iso-flavonoids were purchased from Indofine or Alexis
Biochemicals and stocks were prepared at 50 mM in dimethyl sulphoxide
(DMSO) with the exception of methylluteolin, which was prepared at 25 mM in
DMSO. The compounds were used at 25, 50, 100, and 200 µM for all
experiments. The maximum DMSO concentration used in experiments was
0.4% (200 µM flavonoid treatment). DMSO at this level did not have any effect
on assays conducted compared to non-DMSO treatment (data not included).
Propidium iodide was purchased from Sigma. RNase was purchased from
Fisher. Trypan Blue was purchased from Hyclone.
Cell Culture
The following human breast cancer cell lines were purchased from the
American Type Culture Collection (ATCC): BT-474, MCF-7, MDA-MB-231, SKBR-3, and ZR-75-1. BT-474, SK-BR-3, and ZR-75-1 were routinely maintained in
RPMI 1640 with L-glutamine (HyClone) and supplemented with 10% bovine
growth serum (BGS) and 1X antibiotic/antimycotic (HyClone) containing 10,000
units of penicillin, 10,000 µg of streptomycin, and 25 µg of Amphotericin B per
milliliter. MDA-MB-231 and MCF-7 cells were maintained in DMEM with highglucose, L-glutamine, and sodium pyruvate, supplemented with 10% BGS and
1X antibiotic/antimycotic. All cell lines were maintained at 37°C in a humidified
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atmosphere containing 5% CO2 and passaged based on recommended dilutions
and confluencies from ATCC. Human Mammary Epithelial Cells (HMEC) were
purchased from Lonza and were maintained in the recommended media with
supplements from Lonza.
Cell Viability Assays
Cell viability was determined using the CellTiter-Glo® Luminescent Cell
Viability Assay (CTG, Promega) or Trypan Blue Exclusion Assay (TBE,
HyClone). For the CTG assay, 0.5 × 104 cells per well were seeded in 96-well
white plates (BD Falcon). After 24h of incubation, media were changed and cells
were exposed to various concentrations of flavonoids and iso-flavonoids. The
CTG assays were initiated at 24, 48, and 72h after exposure to compounds, and
cells were processed following the manufacturer’s recommend protocol. Briefly,
cells were incubated at room temperature on a variable speed shaker for 10 min
with the CTG reagent, mixed briefly by pipetting, and centrifuged at 300 xg to
remove bubbles. Plates were read in a Veritas 96 Well Luminometer (Turner
Biosystems) or a Glo-Max II Multimode Plate Reader (Promega).
For the TBE assay, 0.5 x 105 cells per well were seeded in 6-well culture
dishes. After 24h of incubation, media were changed, and cells were treated with
100 µM flavonoid or DMSO as a control. Cells were harvested by trypsinization
at 24, 48, and 72h post treatment and resuspended in 1 mL of media. Cells were
briefly vortexed, and an equal volume of cell suspension was combined with an
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equal volume of 0.4% Trypan Blue in PBS. Cells lacking Trypan Blue were
counted using a hemocytometer, and the percentage of live cells was calculated.
Cell Cycle Analysis
Progression through the cell cycle was analyzed following a previously
published protocol [142]. Briefly, MDA-MB-231 cells were seeded at 0.5 x 105
cells per well in 6-well culture dishes. After 24h of incubation, cells were treated
with 100 µM of various flavonoids. Cells were harvested via trypsinization 24 and
48h after treatment, washed with cold PBS, and processed for cell cycle analysis.
The cells were fixed in absolute ethanol and stored at −20°C for later analysis.
The fixed cells were centrifuged at 1000 rpm and washed with cold PBS twice.
RNase A (20 µg/mL final concentration) and Propidium iodide staining solution
(50 µg/mL final concentration) was added to the cells. The cells were incubated
for 30 min at 37°C in the dark. The cells were analyzed using a FACSCalibur
instrument (BD Biosciences) equipped with CellQuest, and 10,000 events were
collected for analysis.
Statistical Analysis
Statistical data were analyzed for the CTG assay using a four-factor
ANOVA model for drug, cell-line, drug concentration, and time. F-tests followed
by Tukey’s multiple comparison adjustment were utilized to identify statistically
significant differences in cell death. To compare cell death as measured by CTG
and TBE, p-values were calculated from two-sided Student t-tests followed by
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Hochberg multiple comparison adjustments. Only adjusted p-values of <0.05
were considered statistically significant.
For comparison of cell viability to cell cycle arrest, 95% confidence
intervals were computed for G2 fold change of one (no change) and plotted
against cell viability as determined by TBE assays. Dose-response data were
analyzed using sigmoidal curve fits in Prism (GraphPadSoftware, Inc) with
variable slope to determine IC50 values. The top part of the curve was set to
100% response (0% viability) and the bottom part of the curve to 0% (100%
viability). The IC50 values are reported with 95% confidence intervals.
For comparison between two groups in all other assays, the data were
analyzed using the two-sided, two independent sample Student t-test with 95%
confidence intervals reported. A p-value of <0.05 was regarded as statistically
significant.
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RESULTS
Flavonoid-Induce Cellular Cytotoxicity
We measured cell viability of five human breast cancer cell lines (Table 1)
and human mammary epithelial cells (HMEC) after treatment with fourteen
different flavonoids (Table 2) using two assays. First, we used Promega’s
CellTiter-Glo® (CTG) Luminescence assay, which indirectly determines the
number of viable cells by quantifying the amount of ATP present in a
metabolically active cell [143]. This assay has been previously used to measure
amount of cytotoxicity. The CTG assay utilizes a luciferase reaction producing
light output to measure the amount of intracellular ATP. This assay was chosen
over the conventional MTT or MTS assay because flavonoids have been shown
to absorb light at the same wavelength as MTT and MTS assays [144, 145],
which may interfere with the proper interpretation of the data. Secondly, we used
a classical trypan blue exclusion (TBE) assay to measure the number of viable
cells. After treatment with flavonoids, live cells do not take up trypan blue dye
because the membrane is intact, and the cells appear clear under the
microscope.
Cellular viability was measured at 24, 48, and 72h after treatment with
flavonoids at four concentrations of 25, 50, 100, and 200 µM (see Appendix B).
Figures 3 through 6 present the cellular viability measured by the CTG assay
after 72h of treatment with the four concentrations. Cellular viability decreased
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Percent Cell Viability

25 µM Treatment

Flavonoids
Figure 3. Analysis of cell viability for five breast cancer cell lines and one
primary cell line after treatment with 25 µM of flavonoids. The CTG assay
was performed 72h after treatment. The DMSO-treated cell group was set to
100% cell viability, indicated by a horizontal line. Flavonoids used in the study
are indicated along the X-axis. The Y-axis represents the percent cell viability.
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Percent Cell Viability

50 µM Treatment

Flavonoids
Figure 4. Analysis of cell viability for five breast cancer cell lines and one
primary cell line after treatment with 50 µM of flavonoids. The CTG assay
was performed 72h after treatment. The DMSO-treated cell group was set to
100% cell viability, indicated by a horizontal line. Flavonoids used in the study
are indicated along the X-axis. The Y-axis represents the percent cell viability.
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Percent Cell Viability

100 µM Treatment

Flavonoids
Figure 5. Analysis of cell viability for five breast cancer cell lines and one
primary cell line after treatment with 100 µM of flavonoid. The CTG assay
was performed 72h after treatment. The DMSO-treated cell group was set to
100% cell viability, indicated by a horizontal line. Flavonoids used in the study
are indicated along the X-axis. The Y-axis represents the percent cell viability.
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Percent Cell Viability

200 µM Treatment

Flavonoids
Figure 6. Analysis of cell viability for five breast cancer cell lines and one
primary cell line after treatment with 200 µM of flavonoids. The CTG assay
was performed 72h after treatment. The DMSO-treated cell group was set to
100% cell viability, indicated by a horizontal line. Flavonoids used in the study
are indicated along the X-axis. The Y-axis represents the percent cell viability.
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over time and increasing flavonoid concentration. Data were analyzed for the
CTG assay using a four-factor ANOVA model for drug, cell line, drug
concentration, and time. F-tests followed by Tukey’s multiple comparison
procedure were used to find statistically significant differences in cell death. An
ANOVA table with the prospective p-values for this comparison is presented in
Appendix A. There was a significant time-dose effect on cytotoxicity by the
flavonoids in all cancer cell lines, as well as HMECs, tested. Maximum cell death
was measured at 72h after initial treatment (p<0.001). Surprisingly, the data
suggested that some flavonoids stimulated cellular proliferation, especially at the
lower concentrations with data points at a higher than 100% cell viability as
shown in Figure 3 (also see Appendix B).
Becaues the CTG assay determines the number of viable cells indirectly,
by quantifying the amount of ATP, we also conducted the TBE assay in order to
measure the actual number of viable cells. By comparing these data with the
CTG, we were able to identify wether a viability of higher than 100% was due to
stimulation of the cells or was a result of the increase in the amount of ATP
produced by the cells. We chose to measure only cellular viability after 72h of
treatment with flavonoids since this time point showed the maximum effect, as
determined in the CTG assays. These results suggested that the two assays,
CTG and TBE, did not show the same amount of cellular viability (Figure 7). The
majority of the data points lie on the left side of the line indicating a lower TBE
percentage and higher CTG percentage. The results appear as a bar graph in
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Percent Cell Viability-Trypan Blue Exclusion (TBE)

Figure 7. Comparative analysis of cell viability in CTG
and TBE after 72h of flavonoid treatment at four
different concentrations. The key to flavonoids is
provided on the right. The X-axis represents percent cell
viability from TBE. The Y-axis represents percent cell
viability from CTG.	
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Appendix C. Apigenin, chrysin, genistein, kaempherol, luteolin, and quercetin
consistently showed a higher cell viability using the CTG assay than the TBE
assay for all cell lines tested. This suggested that these compounds were
capable of increasing the amount of ATP present in the cells.
In addition, IC50 curves were calculated for all flavonoids after 72h of
treatment using the results from the TBE assay. Table 8 shows the calculated
IC50s with 95% confidence interval ranges indicated in parenthesis. Table 9 is a
summary of the findings regarding cell death in breast cancer cell lines.
Categories are based on the percent viability by TBE in combination with the
IC50 data and grouped flavonoids based on how effectively they induced cellular
cytotoxicity. Apigenin, m-apigenin, and luteolin were the most effective at
inducing cytotoxicity in all cell lines tested. In certain cell lines, quercetin, mquercetin, m-luteolin, kaempherol and chrysin were also very effective at
inducing cytotoxicity but were ineffective in other cell lines. Genistein, mnaringenin, and daidzein were very weak inducers of cytotoxicity in all breast
cancer cell lines. Finally, myricetin, naringenin, and catechin were unable to
induce cytotoxicity in any of the breast cancer cell lines tested. These results
indicated that not all flavonoids were capable of inducing cytotoxicity in breast
cancer cell lines.
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Table 8. IC50 data for flavonoid-induced cell death after 72h. Values are
reported in µM. Values in the parenthesis are the range for the 95% confidence
interval. A value of >200 µM indicates that flavonoid did not induce cellular
death. M-apigenin represents methylapigenin.
	
  
BT-474

MCF-7

MDA-MB-231

SK-BR-3

ZR-75-1

49
(43-56)
42
(35-52)

2
(0.33-16)
40
(17-94)

14
(11-19)
33
(27-40)

32
(23-46)
53
(36-77)

14
(43-48)
38
(18-62)

>200

>200

>200

>200

>200

80
(66-95)
154
(129-182)
97
(61-154)
77
(62-96)
13
(6-27)

34
(28-40)
102
(80-130)
74
(52-105)
25
(16-40)
5
(14-20)

>200

>200

34
(27-42)
97
(69-139)
30
(18-53)
48
(40-58)
13
(9-20)
133
(87-200)

59
(48-72)

M-luteolin

40
(35-45)
179
(144-222)
51
(43-61)
38
(31-47)
16
(14-20)
21
(12-38)

Myricetin

>200

>200

>200

>200

Naringenin

>200

>200

>200

>200

>200

69
(58-82)

102
(64-161)
102
(62-161)
105
(64-171)

75
(59-96)
101
(82-124)
54
(39-75)

72
(54-96)
64
(55-75)
78
(50-123)

40
(22-74)
47
(29-77)

Apigenin
M-apigenin
Catechin
Chrysin
Daidzein
Genistein
Kaempherol
Luteolin

M-naringenin
Quercetin

>200

M-quercetin

>200

38

>200
81
(68-96)
80
(61-106)
32
(28-37)
150
(100-225)
160
(77-330)

>200

Table 9. Summary of findings for cell death using the TBE assay and IC50
values. Categories were created based on strong killing (>80% and IC50<50
µM), weak killing (20-70% and IC50<100 µM), or no killing (<20%).
Kills Strongly (>80%)
Non-Selective
Selective
Apigenin
Chrysin
Methylapigenin
Genistein
Luteolin
Kaempherol
Methylluteolin
Quercetin
Methylquercetin

Kills Weakly
(20-70%)
Daidzein
Methylnaringenin

Does Not Kill
(>20%)
Naringenin
Catechin
Myricetin

Cell Cycle Arrest does not Correlate with Cell Death
The ability of flavonoids to induce cell cycle arrest was assessed by flow
cytometry, and the data were compared to cellular viability by the TBE assay. All
breast cancer cell lines were treated with 100 µM flavonoid and processed at 24
and 48h post-treatment. Figure 8 represents fold change in G2/M DNA content
of flavonoid-treated cells from DMSO-treated control compared to the cell viability
data calculated by the TBE assay. Points to the right of the confidence intervals
indicate a significant increase in DNA content due to an arrest in the G2/M
phase. Points to the left of the confidence intervals indicate a decrease in DNA
content due to an arrest in the G1 phase. Table 10 summarizes the cell cycle
arrest findings. Besides catechin, all the flavonoids arrested the cell cycle of the
different breast cancer cell lines either at the G1 phase or the G2/M phase, and
the arrests were statistically significant (p<0.05).
The majority of flavonoid-induced cell cycle arrest was in the G2/M phase
with the exception of m-quercetin and m-naringenin, which consistently arrested
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48h

Percent Cell Viability (TBE)

24h

Fold G2/M Change
Figure 8. Cell cycle arrest does not correlate with cell
viability. We measured cell cycle arrest at 24 and 48h
treatment with 100 µM flavonoids and plotted the results against
cellular viability as measured by TBE assay. The X-axis has the
fold G2/M DNA content change compared to DMSO-treated
control. The Y-axis represents the cell viability from the TBE
assay. The key to the flavonoids is provided on the right.
Vertical bars indicate the 95% confidence interval for no
significant change in G2/M DNA content in treated cells.
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cell lines in G1 phase. It has been previously shown that methylated versions of
various flavonoids arrest cells in the G1 phase [110], and our data supported
these findings.
It is noteworthy that cell cycle arrest did not occur in all cell lines for a
particular flavonoid (Table 10). For example, apigenin and chrysin arrested all
breast cancer cell lines in G2/M phase with the exception of SK-BR-3 cells.
Another group reported that apigenin is able to induce cell cycle arrest in SK-BR3 cells [41] . We were unable to reproduce this result. However, apigenin does
induce cytotoxicity in SK-BR-3 cells and is similar to what was reported by this
group. Therefore, it remains inconclusive whether or not cell cycle arrest occurs
upon apigenin treatment in SK-BR-3 cells.
Kaempherol and quercetin were the only two flavonoids that consistently
arrested all cell lines tested at both 24 and 48h. Kaempherol is also a very
strong inducer of cellular cytotoxicity in all cell lines, whereas quercetin is more
selective in its cytotoxicity. Naringenin, daidzein, m-luteolin, and myricetin are all
compounds that were not able to induce cellular cytotoxicity at very high levels.
All of these compounds were able to induce cell cycle arrest in some cell lines,
but not others. Taken together, these results suggest that cell cycle arrest may
not be a strong indicator of whether or not a flavonoid is able to induce cellular
cytotoxicity. From these data, we can conclude that flavonoids are able to exert
their effects regardless of cell line used.

41

Table 10. Summary of cell cycle arrest identified in all breast cancer cell
lines after 24 and 48h with 100 µM flavonoid treatment. NE indicates that
there was no cell cycle arrest detected that was statistically significant. G2
corresponds to arrest during the G2/M phase, G1 corresponds to arrest during
the G1 phase, and when indicated was statically significant (p<0.05). Results
shown represent the averages of at least three independent experiments.

Apigenin
M-apigenin
Catechin
Chrysin
Daidzein
Genistein
Kaempherol
Luteolin
M-luteolin
Myricetin
Naringenin
M-naringenin
Quercetin
M-quercetin

BT-474
24
48
G2
G2
G2
NE
NE
NE
G2
G2
NE
NE
G2
G2
G2
G2
G2
G2
G2
G1
NE
NE
G2
G2
NE
NE
G2
G2
NE
G1

MCF-7
24
48
G2
G2
G2
NE
G2
NE
G2
G2
G2
NE
G2
NE
G2
G2
G2
G2
NE
G1
NE
G1
G2
NE
NE
G1
G2
G2
G1
G1

MDA-MB-231
24
48
G2
G2
G2
G2
NE
NE
G2
G2
NE
NE
G2
G2
G2
G2
G2
G2
NE
NE
G2
NE
G2
G2
G1
NE
G2
G2
G1
G1
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SK-BR-3
24
48
NE
NE
NE
G2
NE
NE
NE
NE
NE
G1
G2
G2
G2
G2
NE
G1
G1
G1
G2
G2
NE
NE
G1
G1
G2
GE
G1
G1

ZR-75-1
24
48
G2
G2
G2
G2
NE
NE
G2
G2
NE
NE
G2
G2
G2
G2
G2
G2
NE
G1
G2
G2
NE
NE
NE
G1
G2
G2
NE
G1

DISCUSSION
Flavonoid-Induce Cytotoxicity and Apoptosis Appear to be Independent of
a Particular Signaling Pathway
	
  
We undertook a comprehensive study evaluating flavonoid-induced
cellular cytotoxicity. We used a variety of breast cancer cell lines and flavonoids
to characterize this cellular cytotoxicity. We chose the cell lines based on their
lack of expression in various signaling pathways (Table 1). Some of these same
cell lines have been used in previous studies, listed in Table 3, to characterize
the effect of flavonoids on cellular proliferation and cytotoxicity. We chose
flavonoids from various sub-classes (Table 2) in order to determine if there was a
structural-functional relationship within the chemical structures for induction of
cytotoxicity.
Apigenin, m-apigenin, and luteolin induced the strongest cytotoxicity in all
breast cancer cell lines tested. Becasue these compounds induced cytotoxicity
equally well on all cell lines, we concluded that the mechanism of action was
independent of a particular signaling pathway component, such as HER2, p53,
and EGFR.
The isoflavonoids are considered to be phytoestrogens because of their
structural similarity to the mammalian steroid hormone 17β-estradiol. Both have
been reported to bind to the estrogen receptor and activate it [138]. Some breast
cancers have been shown to be dependent on the estrogen receptor for
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sustained growth. Therefore, circulating phytoestrogens could be harmful by
stimulating growth of breast cancer. Interestingly, consumption of foods rich in
phytoestrogens correlates with reduced risk in breast cancer [148]. Our studies
indicate that daidzein is a weak inducer of cellular cytotoxicity regardless of the
cell line tested. However, genistein appears to be selective for ER-negative cell
lines in the ability to induce cytotoxicity.
We have shown that the same flavonoids, which induce cytotoxicity in
breast cancer cells, are able to induce cytotoxicity in HMECs. This is in contrast
to previous reports in the literature, which have indicated that genistein is unable
to decrease cell viability in MCF10A cells (Table 3). However, it should be noted
that all studies we have seen in the literature generally have not done a
comparison of HMECs and MCF10A cells. Our results suggest that flavonoid
action is through a generalized mechanism and that flavonoids may not directly
target cancer cells as previously suggested, although this still remains
controversial.
We also see cellular cytotoxicity occurring with the methylated derivatives
of some of the flavonoids. Of the methylated flavonoids, methylapigenin was
able to induce cytotoxicity at the equivalent level of apigenin, whereas
methylluteolin and methylquercetin were not. Previous studies have shown that
the methylated versions of various flavonoids tend to be more potent than their
unmethylated counterparts [106].

44

By comparing CTG and TBE data, we were also able to show that some
flavonoids increase the amount of ATP within the cell. It is important to consider
that CTG determines number of viable cells according to the amount of ATP in
the cell suspension, and may result in an overestimation of cell viability for these
flavonoids. It has also been reported that MTT and MTS-based methods result in
an underestimation of cytotoxicity due to reduction of MTT and MTS by some
flavonoids and formation of formazan [144]. These results further demonstrate
the need for a careful consideration of the methods utilized for evaluating cellular
proliferation of flavonoids.
Our studies indicate that flavonoid induction of cellular cytotoxicity may be
occurring through a non-classical apoptotic mechanism. We have previously
reported that flavonoids are able to inhibit caspase-3 and caspase-7 at similar
concentrations that induce cytotoxicity in our breast cancer cell lines [149]. We
also showed that flavonoids are cytotoxic to cells, which lack caspase-3 and
caspase-7. Taken together, these results do not suggest a particular signaling
pathway required for the chemopreventative property of flavonoids. Instead, the
data may suggest that the classical apoptosis may not be the primary form of
cellular cytotoxicity and that the importance of individual signaling component
modulating cell growth may be cancer cell type specific. However, more
extensive research into the role of flavonoids in each signaling pathway is still
required.
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Structure-Function Relationship of Flavonoid Effects
We suggest that flavonoids that are able to induce cytotoxicity may do so
in a generalized cellular mechanism. We have been able to identify structural
features, which we believe is important in flavonoid-induced cytotoxicity. Our
data suggested that the flavones and some flavonols were most cytotoxic, while
the flavanones tested were far less effective at killing cancer cells. This further
suggests that the planarity of the benzopyran nucleus may be a key structural
element in cytotoxicity. For example, we noted that both naringenin and (+)catechin were identical to apigenin and quercetin, respectively, with the
exception of the 2,3-double bond on the C-ring. However, both naringenin and
(+)-catechin did not induce cytotoxicity in cell lines tested. Isoflavonoids were
weaker in their ability to induce cytotoxicity. These observations suggest that
flavonoid cytotoxicity requires the compounds to be planar in nature, possess the
2,3-double bond on the C-ring and the B-ring to be attached at the 2-position of
the benzopyran core. We also believe that the planarity of the flavonoid(s) may
be important in their ability to cross the cell membrane and enter the cytosol and
that the B-ring’s position is important for binding to a protein target.
Future Perspective
Significant progress has been made during the past thirty years on not
only efficacy, but also identifying many molecular mechanisms altered by
flavonoids in various cancers. Medicinal plants have played pivotal roles in the
development of new drugs to treat human diseases. Some of the earliest forms
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of chemotherapy originate from natural products derived from both plants and
marine organisms. It is no surprise to see resurgence in the investigation of
natural products for their anti-cancer use. Flavonoids have been shown to be
potent bioactive molecules that possess anticarcinogenic effects. Flavonoids
have also emerged as potential chemopreventative candidates for cancer.
Despite this promise, contradictory results regarding molecular mechanisms of
action have been reported from many laboratories. Although results from in vitro
experiments are not always predictive of medicinal utility, they constitute a
valuable tool for studying the effects of the drug candidate on molecular targets
involved in tumor growth and survival. In addition, much attention has been
given to the gene targets altered by these chemopreventative agents.
Many other techniques, especially cDNA microarray, may provide great
insight into such gene-drug relationship. cDNA microarray enables researchers
to identify many of altered gene expression as result of treating cells with
flavonoids. This will provide bases for analysis of the functional groups and
molecules involved in many process such as tumor growth and progression, cell
cycle, apoptosis, DNA damage, inflammation and even metabolic alterations/
activations. It is also noteworthy that many researchers study the protective
mechanism of such compounds. Since these dietary compounds are not
classified as drugs, flavonoids do not require FDA approval to be available for
consumption [150]. Therefore, a thorough evaluation of their toxicity and drug
interactions is necessary to ensure their safety for the public.
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More extensive studies are also needed on absorption and bioavailability
of flavonoids in the body. In addition, the majority of dietary compounds contain
a mixture flavonoids and other polyphenols. It has been shown that some
flavonoids may have synergistic effects, whereas individually they are not
effective chemopreventative agents [151]. This is more relevant as bioavailability
data limit the concentration of flavonoids in vivo. Therefore, further extensive
studies are necessary.
Consequently, more studies are clearly needed to resolve the conflicting
data, to more fully understand the mechanism(s) of anti-cancer activity of
flavonoids, and to evaluate their potential as therapeutic agents. As proteins that
interact with flavonoids are identified, these discoveries will provide the basis for
rational drug design.
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APPENDICES
Appendix A. Modified 4-Way ANOVA Table for the CTG Cell Viability Data.
	
  
	
  
Source
p-value
Drug
< 1E-300
Dose
< 1E-300
Time
< 1E-300
Cell Line
2.417E-261
Drug*Dose
< 1E-300
Drug*Time
3.187E-209
Drug*Cell Line
< 1E-300
Dose*Time
1.1998E-80
Dose*Cell Line
9.1602E-76
Time*Cell Line
2.0637E-49
Drug*Dose*Time
4.7378E-32
Drug*Dose*Cell Line
< 1E-300
Drug*Time*Cell Line
8.5134E-77
Dose*Time*Cell Line
1.9173E-07
Drug*Dose*Time*Cell Line 2.694E-06
R2= 0.758
	
  
Table 11. Data analysis was conducted for the CTG assay using a fourfactor ANOVA model for drug, dose, time, and cell line. F-tests followed by
Tukey’s multiple comparison adjustment were utilized to identify statistically
significant differences in cell death.
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Measured by CTG Assay.
9A

Percent Cell Viability

25 µM Treatment After 24h

	
  

Flavonoids

Figure 9. The CTG assay was performed after cells were treated with each
flavonoids. The DMSO-treated cell group was set to 100% cell viability, which is
indicated by a horizontal line. Figures 9A-9L represent the CTG data for
concentrations of 25, 50, 100, 200 µM after 24, 48, 72h treatments. The key to
cell lines tested is provided on the right. Flavonoids used in the study are
indicated along the X-axis. The Y-axis represents the percent cell viability.
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Via CTG Assay.
9B

Percent Cell Viability

25 µM Treatment After 48h

Flavonoids
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Via CTG Assay.
9C

Percent Cell Viability

25 µM Treatment After 72h

Flavonoids
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Via CTG Assay.
9D

Percent Cell Viability

50 µM Treatment After 24h

Flavonoids
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Via CTG Assay.
9E

Percent Cell Viability

50 µM Treatment After 48h

Flavonoids
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Via CTG Assay.
9F

Percent Cell Viability

50 µM Treatment After 72h

Flavonoids
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Via CTG Assay.
9G

Percent Cell Viability

100 µM Treatment After 24h

Flavonoids
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Via CTG Assay.
9H

Percent Cell Viability

100 µM Treatment After 48h

Flavonoids
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Via CTG Assay.
9I

Percent Cell Viability

100 µM Treatment After 72h

Flavonoids
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Via CTG Assay.
9J

Percent Cell Viability

200 µM Treatment After 24h

Flavonoids
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Via CTG Assay.
9K

Percent Cell Viability

200 µM Treatment After 48h

Flavonoids
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Appendix B. Cell Viability of Breast Cancer Cell Lines after Flavonoid Treatment
Via CTG Assay.
9L

Percent Cell Viability

200 µM Treatment After 72h

Flavonoids
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Appendix C. Comparinson of CTG and TBE Assays for
Measuring Cell Viability with 100 µM Flavonoid for 72h.
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Figure 10. Bar graphs comparing cell viability between CTG and TBE
assays were created for the cells treated with 100 µM after 72h, and
standard deviations are indicated. Results shown are for all flavonoid
treatments in SK-BR-3 and ZR-75-1 (A), and BT-474, MCF7, and MDA-MB-231
(B).
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Appendix C. Comparison of CTG and TBE Assays for
Measuring Cell Viability with 100 µM Flavonoid for 72h.
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Appendix D. Summary of Significant Differences Between Data for CTG and
TBE Assays.
	
  
Apigenin
M-apigenin
Catechin
Chrysin
Daidzein
Genistein
Kaempherol
Luteolin
M-luteolin
Myricetin
Naringenin
M-naringenin
Quercetin
M-quercetin

BT-474

MCF-7

MDA-MB-231

SK-BR-3

Zr-75-1

200,100,50,25
25
200
25
200,100,50
50
200,50,25
100,50,25
ND
200
ND
ND
100,50,25
ND

200,100,50,25
100,25
ND
200,100,50,25
200,100,50
50
200,50,25
200,100,15
25
50,25
50
50
50
200,50

50,25
25
ND
100,50,25
200,100,50
200,100,50
200,100,50,25
200,50,25
200,100,50,25
25
200,50,25
ND
200,100,50,25
25

200,100,50,25
200
ND
100,50,25
50
200,100,50,25
200,100,50,25
200,50,25
100,50
200
200,100,50
200
200,100,50
100

25
200,100,25
25
200,50,25
ND
ND
200,100,50,25
200,100
200,100
ND
200,100,50,25
200,100,50,25
ND
200,100

	
  
Table 12. Summary of statistical significant differences (p-values <0.05)
noted between CTG and TBE assays. Results shown are after Hochberg
multiple comparison adjustment. ND corresponds to no significant difference.
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